Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC203 TIL in advanced solid tumors
NCT06375187Phase 1Recruiting
- Sponsor
- Juncell Therapeutics
- Start
- May 2024
- Primary completion
- Nov 2026
- Modality
- Gene Editing, Gene Silencing, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC203 in ovarian cancer, endometrial cancer (EC), Cervical Cancer (CC) and 3 more, sponsored by Juncell Therapeutics. Primary endpoints: Maximal Tolerance Dose at 28 days, Dose Limiting Toxicity at 28 days and 1 more. Started May 2024; status: recruiting.
02
Drugs
GC203
03
Conditions
ovarian cancerendometrial cancer (EC)Cervical Cancer (CC)breast cancergastrointestinal cancer
Beyond the preview
Go deeper on NCT06375187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06375187.